Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Uranium Energy Corp (UEC) Price & Performance

ACADIA Pharmaceuticals Inc.Trade
Uranium Energy CorpTrade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs Uranium Energy Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.53 (market cap $5.07B), while Uranium Energy Corp trades at $11.42 (market cap $5.67B). The key difference: ACADIA Pharmaceuticals Inc. and Uranium Energy Corp are close in size by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals.

ACADUEC
Market Cap
$5.07B$5.67B
Sector
HealthEnergy
52-Week High
$29.41$20.14
52-Week Low
$20.06$9.04
Enterprise Value
$4.19B$5.18B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.

Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.

Uranium Energy Corp

UEC trades at $11.64, up 2.28% today, with a bullish technical signal from moving averages. The company reported a net loss of $87.66 million in 2025 despite $66.84 million revenue, with negative profit margins and cash flow challenges. Recent news highlights insider selling and ongoing uranium market optimism. Analyst consensus is strongly bullish with 87.5% buy ratings, though fundamentals show significant financial strain.

UEC presents high-risk exposure to uranium market growth with substantial operational losses and negative cash flow from operations. The stock's premium valuation (P/S 267.84) relies heavily on future nuclear energy adoption, while current financials indicate dependency on financing activities. Near-term catalysts include production ramp-up and licensing approvals, but execution risks and cost pressures remain elevated.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Read more on ACAD

About Uranium Energy Corp

Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.

Read more on UEC